Source: OncLive, June 2025
- Key Takeaways
IMA203 showed acceptable tolerability and early clinical activity in PD-1–refractory metastatic melanoma patients, with no grade 5 adverse events observed. - The therapy achieved a confirmed overall response rate of 56% and a disease control rate of 91% in melanoma patients.
The PRAME-directed TCR T-cell therapy IMA203 displayed acceptable tolerability and showcased early clinical activity in patients with PD-1–refractory metastatic melanoma, according to data from a phase 1 study (NCT03686124) presented during the 2025 ASCO Annual Meeting.1